Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211 (Q80480588)
Jump to navigation
Jump to search
scientific article published on 05 June 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211 |
scientific article published on 05 June 2007 |
Statements
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211 (English)
Daniel R Kuritzkes
Roy M Gulick
Zhaohui Su
Charles Flexner
Michael D Hughes
Paul R Skolnik
Timothy J Wilkin
Robert Gross
Amy Krambrink
Eoin Coakley
Wayne L Greaves
Andrew Zolopa
Richard Reichman
Catherine Godfrey
Martin Hirsch
AIDS Clinical Trials Group 5211 Team